1. Market Research
  2. > Debiopharm S.A. – Product Pipeline Review – 2013

Debiopharm S.A. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 100 pages

Debiopharm S.A. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Debiopharm S.A. - Product Pipeline Review - 2013” provides data on the Debiopharm S.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Debiopharm S.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from Debiopharm S.A. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Debiopharm S.A. - Brief Debiopharm S.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Debiopharm S.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Debiopharm S.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Debiopharm S.A.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Debiopharm S.A.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Debiopharm S.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Debiopharm S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Debiopharm S.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Debiopharm S.A. and identify potential opportunities in those areas.

Table Of Contents

Debiopharm S.A. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Debiopharm S.A. Snapshot 7
Debiopharm S.A. Overview 7
Key Information 7
Key Facts 7
Debiopharm S.A. - Research and Development Overview 8
Key Therapeutic Areas 8
Debiopharm S.A. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Debiopharm S.A. - Pipeline Products Glance 13
Debiopharm S.A. - Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
Debiopharm S.A. Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Debiopharm S.A. - Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Debiopharm S.A. - Drug Profiles 17
alisporivir 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Debio-0617 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Debio-0719 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Debio-0826 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Debio-0827 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Debio-0928 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Debio-0929 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Debio-0930 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Debio-0931 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Debio-0932 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Debio-1036 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Debio-1141 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Debio-1142 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Debio-1347 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
triptorelin pamoate 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Debiopharm S.A. - Pipeline Analysis 34
Debiopharm S.A. - Pipeline Products by Therapeutic Class 34
Debiopharm S.A. - Pipeline Products by Route of Administration 35
Debiopharm S.A. - Pipeline Products By Mechanism of Action 36
Debiopharm S.A. - Recent Pipeline Updates 38
Debiopharm S.A. - Dormant Projects 41
Debiopharm S.A. - Locations And Subsidiaries 42
Head Office 42
Debiopharm S.A., Recent Developments 43
Debiopharm S.A.- Press Release 43
Jun 06, 2010: Curis Achieves Phase I Milestone Under Hsp90 Collaboration With Debiopharm 43
Apr 27, 2010: Debiopharm Begins Phase I Clinical Trial With Debio 0932 43
Mar 12, 2010: FDA Approves Watson's TRELSTAR 22.5mg 44
Feb 12, 2010: Curis Achieves Milestone With Debiopharm Receiving Approval From France's Regulatory Authority For Debio 0932 45
Feb 09, 2010: Novartis Gains Rights To Develop And Market Debio 025 45
Financial Deals Landscape 47
Debiopharm S.A., Deals Summary 47
Debiopharm S.A., Pharmaceuticals and Healthcare, Deal Details 50
Venture Financing 50
Spinomix Raises US$3 Million In Series A Financing 50
Biocartis Raises US$44.7 Million In Series D Financing 52
Agendia Raises US$65 Million In Financing Round 54
Biocartis Secures US$96 Million In Series C Financing Round 56
Diagnoplex Raises Additional Funds In Series A Financing 59
Biocartis Secures US$41.3 Million In Series B Financing Round 60
TcLand Expression Secures US$12.04 Million In Series A Financing 62
Partnerships 64
Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 64
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 66
Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 67
Pfizer Enters Into Co-Development Agreement With Debiopharm 68
Debiopharm Enters Into Agreement With MSM Protein Technologies 70
Debiopharm Enters Into Distribution Agreement With Mepha Pharma 71
Debiopharm Enters Into Research Agreement With Ecole Polytechnique Federale de Lausanne 72
Debiopharm Enters Into Co-Marketing Agreement 73
Debiopharm Enters Into Research Agreement With Kirin Brewery 74
Licensing Agreements 75
Debiopharm Enters Into Licensing Agreement With Medical Futures 75
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 76
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 77
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 79
Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 80
Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 81
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 83
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius and Teva 85
Debiopharm Enters Into Licensing Agreement With Novartis 86
Ipsen Enters Into License Agreement With Debiopharm 87
Curis Enters Into Worldwide License Agreement With Debiopharm 88
Debiopharm Enters Into Licensing Agreement With Mercury Therapeutics 90
Debiopharm Group Enters Into Licensing Agreement With Moffitt Cancer Center 91
Debiopharm Enters Into Licensing Agreement With Aurigene 92
Debiopharm Group Enters Into Licensing Agreement With Pharmaleads 94
Ipsen Extends Its Agreement With Debiopharm 95
Debiopharm Enters Into Licensing Agreement With NanoCarrier 96
Asset Transactions 97
Patrys Acquires PAM-1 From Debiopharm Group 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100



List of Tables

Debiopharm S.A., Key Information 7
Debiopharm S.A., Key Facts 7
Debiopharm S.A. - Pipeline by Indication, 2013 10
Debiopharm S.A. - Pipeline by Stage of Development, 2013 11
Debiopharm S.A. - Monotherapy Products in Pipeline, 2013 12
Debiopharm S.A. - Phase III, 2013 13
Debiopharm S.A. - Phase I, 2013 14
Debiopharm S.A. - Pre-Clinical, 2013 15
Debiopharm S.A. - Discovery, 2013 16
Debiopharm S.A. - Pipeline By Therapeutic Class, 2013 34
Debiopharm S.A. - Pipeline By Route of Administration, 2013 35
Debiopharm S.A. - Pipeline Products By Mechanism of Action, 2013 37
Debiopharm S.A. - Recent Pipeline Updates, 2013 38
Debiopharm S.A. - Dormant Developmental Projects,2013 41
Debiopharm S.A., Deals Summary 47
Spinomix Raises US$3 Million In Series A Financing 50
Biocartis Raises US$44.7 Million In Series D Financing 52
Agendia Raises US$65 Million In Financing Round 54
Biocartis Secures US$96 Million In Series C Financing Round 56
Diagnoplex Raises Additional Funds In Series A Financing 59
Biocartis Secures US$41.3 Million In Series B Financing Round 60
TcLand Expression Secures US$12.04 Million In Series A Financing 62
Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 64
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 66
Debiopharm Group Enters Into Co-Development Agreement With Marina Biotech 67
Pfizer Enters Into Co-Development Agreement With Debiopharm 68
Debiopharm Enters Into Agreement With MSM Protein Technologies 70
Debiopharm Enters Into Distribution Agreement With Mepha Pharma 71
Debiopharm Enters Into Research Agreement With Ecole Polytechnique Federale de Lausanne 72
Debiopharm Enters Into Co-Marketing Agreement 73
Debiopharm Enters Into Research Agreement With Kirin Brewery 74
Debiopharm Enters Into Licensing Agreement With Medical Futures 75
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 76
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 77
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 79
Debiopharm Enters Into Licensing Agreement With Ascenta Therapeutics For AT-406 80
Debiopharm Enters Into Licensing Agreement With Yale University For Debio 1036 81
Debiopharm Enters Into Option Licensing Agreement With Aurigene Discovery Technologies For Debio 1142 83
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius and Teva 85
Debiopharm Enters Into Licensing Agreement With Novartis 86
Ipsen Enters Into License Agreement With Debiopharm 87
Curis Enters Into Worldwide License Agreement With Debiopharm 88
Debiopharm Enters Into Licensing Agreement With Mercury Therapeutics 90
Debiopharm Group Enters Into Licensing Agreement With Moffitt Cancer Center 91
Debiopharm Enters Into Licensing Agreement With Aurigene 92
Debiopharm Group Enters Into Licensing Agreement With Pharmaleads 94
Ipsen Extends Its Agreement With Debiopharm 95
Debiopharm Enters Into Licensing Agreement With NanoCarrier 96
Patrys Acquires PAM-1 From Debiopharm Group 97



List of Figures

Debiopharm S.A. - Pipeline by Indication, 2013 9
Debiopharm S.A. - Pipeline by Stage of Development, 2013 11
Debiopharm S.A. - Monotherapy Products in Pipeline, 2013 12
Debiopharm S.A. - Pipeline By Therapeutic Class, 2013 34
Debiopharm S.A. - Pipeline By Route of Administration, 2013 35
Debiopharm S.A. - Pipeline Products By Mechanism of Action, 2013 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.